Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 5,263 Shares of Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at approximately $1,403,599.54. This trade represents a 2.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Trevi Therapeutics Price Performance

Shares of NASDAQ:TRVI traded up $0.21 during midday trading on Tuesday, hitting $6.61. 1,053,002 shares of the company’s stock were exchanged, compared to its average volume of 994,539. Trevi Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $7.39. The company has a market cap of $639.07 million, a PE ratio of -15.02 and a beta of 0.90. The stock has a 50 day moving average price of $4.65 and a 200-day moving average price of $3.78.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01. On average, analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on TRVI shares. D. Boral Capital reiterated a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a report on Wednesday, March 19th. B. Riley reiterated a “buy” rating and issued a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC cut their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, March 19th. Oppenheimer lifted their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Finally, Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $17.56.

Hedge Funds Weigh In On Trevi Therapeutics

Several large investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. lifted its position in shares of Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after purchasing an additional 2,894 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after buying an additional 6,764 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Trevi Therapeutics in the 4th quarter worth approximately $49,000. Squarepoint Ops LLC bought a new position in shares of Trevi Therapeutics in the fourth quarter valued at approximately $58,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Trevi Therapeutics during the fourth quarter valued at approximately $66,000. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.